Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$0.54.

  • Capricor Therapeutics' EPS (Basic) fell 4210.53% to -$0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6, marking a year-over-year decrease of 5686.27%. This contributed to the annual value of -$1.15 for FY2024, which is 3807.68% down from last year.
  • As of Q3 2025, Capricor Therapeutics' EPS (Basic) stood at -$0.54, which was down 4210.53% from -$0.57 recorded in Q2 2025.
  • Capricor Therapeutics' 5-year EPS (Basic) high stood at $0.02 for Q4 2023, and its period low was -$0.57 during Q2 2025.
  • Its 5-year average for EPS (Basic) is -$0.29, with a median of -$0.28 in 2023.
  • As far as peak fluctuations go, Capricor Therapeutics' EPS (Basic) skyrocketed by 10645.16% in 2023, and later plummeted by 109539.21% in 2024.
  • Capricor Therapeutics' EPS (Basic) (Quarter) stood at -$0.26 in 2021, then fell by 19.23% to -$0.31 in 2022, then soared by 106.45% to $0.02 in 2023, then tumbled by 1095.39% to -$0.2 in 2024, then crashed by 171.25% to -$0.54 in 2025.
  • Its EPS (Basic) was -$0.54 in Q3 2025, compared to -$0.57 in Q2 2025 and -$0.2 in Q4 2024.